Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review

We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer. First-line was defined as treatment for endocrine ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinert, Tomás, Barrios, Carlos H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764151/
https://www.ncbi.nlm.nih.gov/pubmed/29344106
http://dx.doi.org/10.1177/1758834017728928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764151/
https://www.ncbi.nlm.nih.gov/pubmed/29344106
http://dx.doi.org/10.1177/1758834017728928

Ejemplares similares